---
title: "Steroid-primed inflammasome and GR cleavage: open questions in topical corticosteroid limits for a"
id: "frontiers-in-immunology-8-a-putative-pharmacodynamic-ceiling-for-topical-corticosteroids-in-atopic"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-a-putative-pharmacodynamic-ceiling-for-topical-corticosteroids-in-atopic"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1988621"
published_at: "2026-10-22T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Steroid-primed inflammasome and GR cleavage: open questions in topical corticosteroid limits for a
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-a-putative-pharmacodynamic-ceiling-for-topical-corticosteroids-in-atopic
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1988621)
- **Published At:** 2026-10-22T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The article title indicates a proposed pharmacodynamic ceiling for **topical corticosteroids** in **atopic dermatitis**, implicating an inflammasome and **caspase-1**–mediated **glucocorticoid receptor** cleavage. - The source document provided here contains site navigation and journal metadata only; no experimental methods, results, or datasets were included in the supplied content. - Because the supplied content lacks study details, investigators' reported endpoints, dosing regimens, sample sizes, and statistical results are not available and cannot be summarized. - The title suggests a mechanistic hypothesis: prior steroid exposure might prime an innate immune sensor (the inflammasome), activate **caspase-1**, and cleave the **glucocorticoid receptor**, which could limit steroid pharmacodynamics in lesional skin. - The supplied source did not report clinical or preclinical evidence, timelines, or next steps; therefore no claims about efficacy, safety signals, or translational impact can be made from the provided material. - Key unanswered questions that remain from the available content include whether the findings derive from human tissue, animal models, or cell systems; the reversibility of the proposed receptor cleavage; and the clinical relevance to steroid dosing strategies. - Readers should consult the full Frontiers in Immunology article for primary data, since this extracted content does not contain the article body or figures needed to evaluate the hypothesis.
## Clinical Analysis & Structured Key Points
Frontiers | A putative pharmacodynamic ceiling for topical corticosteroids in atopic dermatitis: a steroid-primed inflammasome and caspase-1–mediated glucocorticoid receptor cleavage HYPOTHESIS AND THEORY article Front. Immunol. , 22 October 2026 Sec. Inflammation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1988621 Published in Frontiers in Immunology Inflammation 7 impact factor 11.3 citescore Part of a Research Topic Innate immune signaling and inflammatory amplification in inflammation-driven diseases: mechanisms, biomarkers, and therapeutic targeting Submission open 11k views 13 articles Editor & Reviewers Edited by D G Divya Gopinath Reviewed by A J Alok Jha X L Xin Luo Outline Figures and Tables Figure 1 View in article Table 1 Evidence boundaries of the proposed model. View in article HYPOTHESIS AND THEORY article Front. Immunol. , 22 October 2026 Sec. Inflammation Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1988621 A putative pharmacodynamic ceiling for topical corticosteroids in atopic dermatitis: a steroid-primed inflammasome and caspase-1–mediated glucocorticoid receptor cleavage S S Seung-Yong Seong 1,2,3,4 * 1. Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea 2. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea 3. Wide River Institute of Immunology, Seoul National University College of Medicine, Hongchon, Gangwon, Republic of Korea 4. Shaperon Inc., Seoul, Republic of Korea See more Article metrics View details Abstract Background: Topical corticosteroids (TCS) remain the first-line anti-inflammatory treatment for mild-to-moderate atopic dermatitis (AD), yet continuous use is constrained by cutaneous toxicity, rebound phenomena and topical steroid withdrawal (TSW). Objective: This article proposes a mechanistic model in which glucocorticoids prime a cutaneous inflammasome axis that both sustains relapse risk and progressively reduces glucocorticoid receptor (GR) availability through caspase-1-mediated cleavage. Methods: A narrative, hypothesis-generating synthesis integrated clinical trials of proactive maintenance and non-steroidal topicals with mechanistic data on glucocorticoid signaling, NLRP3 inflammasome biology, purinergic P2X7 receptor (P2X7R) pathways, keratinocyte-immune crosstalk and GR regulation. Hypothesis: TCS are among the most effective topical agents for AD, but prolonged use is associated with steroid-associated rosacea-like dermatitis and TSW, iatrogenic phenotypes with no non-steroidal counterpart. Residual relapse under proactive maintenance is of comparable magnitude whether maintenance is steroidal or non-steroidal and is therefore taken here as the clinical problem to be solved. Glucocorticoids can transactivate NLRP3 in myeloid cells and induce CCL20 and TLR2 in keratinocytes, increasing inflammasome sensor abundance and sensitivity. On tapering or withdrawal, under continued subclinical type 2 inflammation, barrier disruption, microbial colonization and LL-37 and ATP release, the primed P2X7R-NLRP3 axis may discharge. In leukemia cells, active caspase-1 cleaves GR, reducing receptor occupancy at glucocorticoid-responsive elements and conferring steroid resistance; analogous activity in skin would be expected to narrow progressively the GR pool available to subsequent TCS doses. Conclusions: The model reframes steroid-associated rosacea-like dermatitis and TSW as predictable discharges of a pharmacologically primed inflammasome rather than as idiosyncratic toxicity, with the limit on prolonged TCS use proposed to be set by P2X7R-NLRP3-caspase-1-GR interactions. It favors an add-on strategy co-administered with TCS from induction onward, targeting inflammasome assembly or caspase-1 activity to preserve GR integrity and prolong safe first-line steroid use, rather than relying on second-line non-steroidal substitution alone. No new experiments, patient-level analyses or meta-analyses are presented; prospective studies should quantify inflammasome activation, extracellular ATP and GR cleavage in human skin across the induction, maintenance, tapering and withdrawal phases of TCS therapy. 1 Introduction Topical corticosteroids (TCS) are widely accepted as first-line anti-inflammatory treatment for mild-to-moderate atopic dermatitis (AD) ( 1 – 3 ). In routine practice, mild-to-moderate AD is managed with regular emollient use and topical corticosteroid treatment of active lesions until adequate disease control is achieved, generally during a short induction course with reassessment within several weeks ( 2 , 4 – 6 ). Once disease control has been achieved, guideline-supported proactive therapy consists of intermittent treatment of previously affected, flare-prone sites with a topical anti-inflammatory agent, commonly a corticosteroid applied twice weekly—while emollient therapy is continued ( 2 , 4 , 5 , 7 ). It is within this induction-to-maintenance sequence that a duration limit restricting prolonged TCS exposure may become clinically relevant. Multiple guidelines endorse TCS in this position. The American Academy of Dermatology strongly recommends TCS for adults with AD and supports intermittent medium-potency TCS as twice-weekly maintenance therapy ( 2 ). Chinese guidelines similarly designate TCS as first-line therapy ( 3 ), and European guidance recommends the same proactive approach ( 5 ). Surveys of international dermatologists confirm that TCS are viewed as the mainstay topical anti-inflammatory treatment and are commonly used proactively on previously involved sites ( 4 ). Network meta-analyses reinforce this positioning. A Cochrane review of almost 300 randomized trials in eczema placed potent TCS, topical Janus kinase inhibitors (JAKi) and tacrolimus 0.1% among the most effective topical treatments ( 8 ). In these analyses, short-term TCS use at any potency did not significantly increase clinically apparent skin thinning, and atrophy remained uncommon even over extended treatment durations ( 8 ). More recent evidence syntheses underpinning joint American guidelines similarly found that mid-potency corticosteroids improved multiple patient-important outcomes with moderate-to-high certainty and ranked among the best topical therapies on composite benefit metrics, ahead of several non-steroidal agents ( 1 ). Thus, TCS are not weak medications displaced by superior alternatives; rather, they are potent and effective agents constrained by a relatively narrow therapeutic window ( 1 , 8 , 9 ). This asymmetry-robust anti-inflammatory efficacy paired with concerns about duration-dependent safety and rebound-serves as the premise for this hypothesis article. Accordingly, this Hypothesis and Theory article explores potential receptor-level mechanisms underlying this limited responsiveness. For this hypothesis article, a “pharmacodynamic ceiling” is an exposure-conditioned reduction in the response of viable skin cells to an equivalent local glucocorticoid exposure, relative to their pretreatment state or an appropriately matched control. “Ceiling” is used as conceptual shorthand for diminished responsiveness, not as a measured maximal dose–response plateau. In practice, the major constraints on TCS use are tolerability, safety concerns, and fear of rebound. Guidelines restrict continuous TCS use to short-term courses and recommend dose adjustment or treatment modification if an adequate response is not achieved within around four weeks ( 6 ). The most prominent adverse effect is skin atrophy, which is potentiated by higher potency, occlusion, thin skin, and older age ( 9 ). Long-term application of potent TCS to facial skin can lead to confluent erythema, telangiectasia, and papulopustular eruptions that resemble rosacea and are frequently followed by characteristic rebound upon discontinuation ( 10 , 11 ); steroid-associated rosacea has been reported to differ from non-steroid-associated rosacea in eyelid involvement and serum cortisol, although in retrospective data only ( 12 ). Relatedly, topical steroid withdrawal (TSW) has been described as intense erythema, burning, and papulopustular eruption after cessation of prolonged TCS use, particularly on the face, but its mechanisms remain controversial and poorly defined ( 13 – 16 ). Corticosteroid phobia is widespread, reinforced by these phenomena and by patient information from non-specialist sources ( 17 ). Large international surveys using the TOPICOP scale show substantial fears about TCS safety among patients and caregivers ( 18 , 19 ), resulting in underdosing, self-reduction of frequency, and premature discontinuation ( 20 ). These behavioral constraints compound pharmacological ones, effectively lowering the real-world ceiling on TCS exposure. Importantly, even when TCS are deployed according to guidelines, proactive therapy does not abolish relapses. In proactive fluticasone regimens, roughly one fifth to two fifths of adults and adolescents relapsed within 16 weeks despite twice-weekly TCS maintenance ( 21 ), and a vehicle-controlled trial in children with mild-to-moderate disease gave a residual of the same order ( 22 ). In a pediatric trial of crisaborole-based proactive maintenance, almost half of participants relapsed within 16 weeks following a TCS induction phase ( 23 ), and in a 52-week vehicle-controlled maintenance study most enriched responders flared at least once within the year ( 24 ). Where a non-steroidal agent has been used as needed rather than on a fixed schedule, more than half of patients experienced disease worsening within the year, although control was regained: in a pooled analysis of as-needed ruxolitinib cream the median time to worsening to IGA 2 or above was 36.1 weeks, IGA 0/1 was quickly recaptured, and patients spent a median 43.9% of the as-needed period off treatment ( 25 ), while 74.1% to 77.8% of patients were at IGA 0/1 at Week 52 ( 26 ). Thus, both steroidal and non-steroidal proactive strategies leave a sizeable residual relapse fraction over months ( 7 ). Because that fraction is of the same order whether maintenance is steroidal or non-steroidal, relapse rate alone cannot distinguish a steroid-primed mechanism from steroid-independent relapse: it defines the unmet need rather than supporting the hypothesis. The phenomena that have no non-steroidal counterpart, steroid-associated rosacea-like dermatitis and TSW, carry that discriminating weight instead. In parallel, therapeutic innovation has focused on second-line non-steroidal agents-calcineurin inhibitors, phosphodiesterase-4 inhibitors, and more recently JAKi and aryl hydrocarbon receptor agonists-tested primarily in patients deemed unsuitable for or uncontrolled by TCS ( 27 – 29 ). Indirect comparisons rank several of these agents highly on short-term endpoints ( 30 , 31 ), and one has been compared directly with a corticosteroid in a dose-ranging study ( 32 ). Many of these agents are effective and clinically useful, but they do not directly address how TCS themselves may load risks during otherwise successful therapy. If the main limitation of TCS is not lack of efficacy but the emergence of iatrogenic pathology and rebound at longer durations, then the most impactful innovation may be an add-on strategy that neutralizes steroid-specific liabilities while preserving their first-line role ( 33 ). The clinical observations motivating this hypothesis include: (i) steroid-associated rosacea-like dermatitis and TSW after prolonged TCS use ( 10 , 11 , 14 , 16 ); (ii) persistent subclinical inflammation and barrier abnormalities even in clinically normal-appearing AD skin ( 34 – 36 ); (iii) relapse despite proactive steroidal or non-steroidal maintenance ( 7 , 21 – 24 ), which frames the unmet need; and (iv) clinical impressions of reduced responsiveness or residual relapse to TCS in some settings, which controlled studies in psoriasis have not confirmed ( 37 , 38 ). They are not assumed to have one cause. Persistent type 2 inflammation, barrier dysfunction, tissue-resident immune cells, microbial factors, and treatment adherence provide alternative explanations for recurrence. Those results cannot establish an AD-specific mechanism but argue against presuming universal loss of TCS efficacy. Throughout, damage-associated molecular patterns (DAMPs) refer to endogenous molecules released or exposed by stressed or injured tissue that can initiate innate immune responses ( 39 ). The proposed model asks whether glucocorticoid-sensitive inflammasome signaling, potentially involving different sensors in different skin compartments, could converge on caspase-1 and reduce functional GR. This is a mechanistic extrapolation, not an established explanation for AD relapses. 2 Evidence synthesis This work is a perspective and hypothesis-generating article. It synthesizes existing published data to generate a testable model and does not involve new human or animal experiments. Four evidence streams inform the synthesis: Clinical trial data on TCS and non-steroidal topical agents in AD, with emphasis on induction regimens, proactive maintenance strategies, relapse rates, and cutaneous safety profiles. Observational and regulatory reports on steroid-induced rosacea-like dermatitis, TSW, and perceptions of corticosteroid “tachyphylaxis,” including systematic reviews and pharmacovigilance data when available. Mechanistic studies in myeloid cells, keratinocytes, and mouse models addressing glucocorticoid effects on NLRP3 inflammasome components, purinergic ATP–P2X7R signaling, LL-37 and TLR2 pathways, and itch–scratch-related DAMPs signaling in skin. Translational studies on inflammasome activity, caspase-1-mediated GR cleavage, and glucocorticoid resistance in hematologic malignancies, nephrotic syndrome, asthma, chronic rhinosinusitis with nasal polyps, depression, and inflammatory dermatoses. The narrative synthesis draws on electronic literature searches supported by AI-assisted retrieval, reference-list screening and authoritative guidelines. Topics included combinations of “atopic dermatitis,” “topical corticosteroid,” “inflammasome,” “NLRP3,” “P2X7,” “LL-37,” “caspase-1,” “glucocorticoid receptor,” “steroid resistance,” “rosacea,” and “topical steroid withdrawal.” Evidence is classified by what each study demonstrates, not by whether it is compatible with the model. “Demonstrated in the original system” identifies experimental findings together with their cell type, species, and exposure context; it does not imply demonstration in TCS-exposed AD epidermis. “Indirect support” identifies related observations that do not test the proposed causal link. “Untested hypothesis” identifies the extrapolations that require direct validation. Table 1 applies this classification, and Figure 1 illustrates the proposed GR-cleavage mechanism, candidate NLRP3 branch, and conditional add-on strategy. The first proposed component is conditional glucocorticoid-dependent sensitization of an inflammasome pathway in an identified skin compartment. NLRP3 is a candidate because of the myeloid priming data, not because its dominance in human keratinocytes has been established. The second proposed component is activation by disease- or injury-associated signals during treatment or after dose reduction, with NLRP1 and NLRP3 considered separately. The third is caspase-1-dependent cleavage of GR within the affected GR-expressing cell, leading to impaired response at equivalent local glucocorticoid exposure. None of these linked events have been established as a complete sequence in TCS-exposed human AD skin. Table 1 Link/observation Evidence and original system Not established in TCS-exposed AD skin Glucocorticoid → NLRP3/ATP sensitization GR-dependent responses in differentiated macrophage systems ( 40 ); neuroimmune support ( 41 – 43 ). Direction and magnitude in skin; keratinocyte priming; persistence after tapering. Glucocorticoid → inflammasome suppression Pro-IL-1β suppression and timing-dependent inhibition in macrophages ( 44 – 46 ). A skin exposure window in which priming outweighs suppression. CCL20/TLR2/LL-37 observations Keratinocyte responses, antimicrobial-peptide suppression, and separate rosacea studies ( 47 – 57 ). A single steroid-induced cutaneous amplification sequence. NLRP1 → cytokine release Human keratinocyte and AD-associated studies, including S. aureus challenge and NLRP1 silencing ( 58 , 59 ). Steroid-induced NLRP1 priming, P2X7R dependence, or GR cleavage. Dermal Myeloid contribution to AD Human dermal macrophage/inflammasome and spatial-network observations ( 60 , 61 ); topical/oral TDCA mouse studies ( 62 , 63 ). Macrophage-exclusive causality, TCS-induced priming, GR cleavage, or reversal of steroid resistance. GPCR19–P2X7R–NLRP3 modulation microglial and knockout experiments in Alzheimer disease models ( 64 ). The same response in dermal myeloid cells; a glucocorticoid challenge or GR-preserving effect. Caspase-1 → GR cleavage/resistance Leukemia and recombinant-protein experiments; perturbation and rescue ( 65 , 66 ). Cleavage in viable skin cells at clinically relevant local exposure. Residual relapses during maintenance Clinical TCS and nonsteroidal maintenance studies ( 7 , 21 – 26 ). A shared inflammasome driver or a TCS-specific pharmacodynamic ceiling. Integrated pathway/adjunct benefit Linked interpretation of separate published observations. The complete same-cell sequence, clinical frequency, GR preservation, or longer safe TCS use. Evidence boundaries of the proposed model. Figure 1 Proposed steroid-primed inflammasome–caspase-1–GR axis. Solid arrows mark steps demonstrated in the experimental system; dashed arrows mark proposed steps that have not been demonstrated in TCS-exposed human skin. (A) Reduced TCS responsiveness. Active caspase-1 cleaves the GR, reducing the pool of intact receptor; the consequent fall in GR-dependent signaling and in responsiveness to an equivalent glucocorticoid exposure is the proposed pharmacodynamic ceiling. (B) TCS-induced inflammasome priming, proposed in TCS-exposed atopic dermatitis skin. Left panel, glucocorticoids acting through GR-dependent transcription raise NLRP3 mRNA and protein and increase sensitivity to extracellular ATP in macrophage systems ( 40 ). Right panel: DAMPs, principally extracellular ATP, act on P2X7R with K+ efflux to supply the activation signal by itch-scratch cycle etc. ( 67 – 69 ). The two inputs converge on the NLRP3 inflammasome, activating caspase-1 and driving IL-1β and IL-18 maturation. NLRP3 is drawn as the candidate branch because the glucocorticoid-priming data exists for it; NLRP1 is a complementary upstream route in human keratinocytes, including the S. aureus -associated response ( 59 ), and is not shown. (C) Proposed add-on strategy. An inflammasome inhibitor co-administered with TCS from induction onward is proposed to reduce inflammasome assembly and caspase-1 activity, thereby preserving intact GR and maintaining the TCS response while lowering IL-1β and IL-18 maturation. The intervention targets the convergent node and is therefore independent of which sensor is upstream. No formal systematic review or meta-analysis was attempted, and risk-of-bias tools were not applied, given the mechanistic and conceptual focus. Consequently, clinical associations and findings from separate experimental systems cannot be combined to estimate the frequency, magnitude, or clinical impact of the proposed mechanism. 3 The proposed model 3.1 Glucocorticoids as paradoxical primers of the inflammasome Human skin expresses both NLRP1 and NLRP3, although their expression and functional contributions vary with cellular compartment and inflammatory context ( 58 , 70 ). Sand et al. ( 58 ) demonstrated NLRP1-dependent IL-1β and IL-18 release following UVB irradiation of human primary keratinocytes, together with substantial difference
## Related Clinical Research

- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)
- [ADHD and dementia risk: new study links ADHD to later-life cognitive impairment](https://medichelpline.com/clinical-feed/medical-news-today-1-is-adhd-a-risk-factor-for-dementia-new-research-suggests-it-might-be.md)
- [How pre-vaccination immunity heterogeneity drives variability in vaccine effectiveness estimates](https://medichelpline.com/clinical-feed/medrxiv-5-heterogeneity-in-pre-vaccination-population-immunity-can-contribute-to.md)
- [Progression of multiple long-term conditions (multimorbidity) in England: a population-based descriptive study of 49·6 million adults](https://medichelpline.com/clinical-feed/the-lancet-public-health-7-progression-of-multiple-long-term-conditions-multimorbidity-in-england-a-population-based-descriptive-study-of-49-6-million-adults.md) (DOI: 10.1016/S2468-2667(26)00052-6)
- [InControl web platform pilot assessing usability and feasibility in older adults with chronic musc](https://medichelpline.com/clinical-feed/plos-one-13-feasibility-acceptability-and-usability-of-incontrol-web-platform-intervention.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.